Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Conteduca V, Ku S-, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, et al. Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. NPJ Precis Oncol. 2021;5(1):76.

Bortoletto P, Romanski PA, Schatz-Siemers N, Spandorfer SD. Retained products of conception as an aetiology for endometritis. BJOG. 2021.

Sangiorgio VF, Nam A, Chen Z, Orazi A, Tam W. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms. Leuk Res. 2021;100:106495.

Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, et al. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Res. 2021;81(18):4736-4750.

Iyengar NM, Zhou XK, Mendieta H, Giri DD, El-Hely O, Winston L, et al. Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. Cancer Prev Res (Phila). 2021;14(5):541-550.

Wang TZ, Simon MS, Westblade LF, Saiman L, E Furuya Y, Calfee DP. Quantitative characterization of high-touch surfaces in emergency departments and hemodialysis facilities. Infect Control Hosp Epidemiol. 2021;42(4):474-476.

Perez VA, Husain S, Magro CM, Strom MA, Williams KM, Levin LE. A newly described cutaneous reaction at sites of insulin pump use in a child with Type 1 diabetes. Pediatr Dermatol. 2021;38(1):239-241.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Sakunrangsit N, Metheepakornchai P, Kumpunya S, Greenblatt MB, Leelahavanichkul A, Pisitkun P, et al. Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model. PLoS One. 2021;16(4):e0250215.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.